Skip to content

Optimization of benign prostatic hyperplasia treated with Awn Needle

Optimization of benign prostatic hyperplasia treated with Awn Needle

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015861
Enrollment
Unknown
Registered
2018-04-25
Start date
2018-04-30
Completion date
Unknown
Last updated
2018-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Interventions

Awn needle group:Acupuncture of Awn Needle
Filiform needle group:Acupuncture

Sponsors

First Hospital Affiliated to Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 50-75 years; 2. Diagnostic criteria for benign prostatic hyperplasia in Western Medicine; 3. According to the diagnostic criteria of traditional Chinese medicine Jing Long disease; 4. Not taking drugs for the treatment of benign prostatic hyperplasia within a week; 5. Observation cases in patients with enlarged prostate volume measured by color Doppler ultrasound; 6. Lookup cooperation Fluent and fluent language Accurate expression Unconscious and cognitive handicapped; 7. Voluntary participation in this test and the signing of the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who do not meet the above diagnostic criteria; 2. Recurrent urinary tract infection; 3. Urethral malformation urethral stricture Neurogenic bladder disease Suspected prostate cancer patients; 4. A patient with a serious need for surgery or A patient with a history of prostate surgery; 5. Poor control of diabetes and Diabetic neuropathy; 6. Mental illness and Manic and Depressant; 7. Other benign prostatic hyperplasia treated in one week; 8. Participating in other clinical trials; 9. The patients with severe heart disease, liver dysfunction (ALT AST, 1.5 times higher than the upper limit of normal) and renal insufficiency (Cr beyond the upper limit of the normal value of BUN, 1.2 times higher than the upper limit of the normal value), a serious disease of hematopoietic system and metabolic system etc.

Design outcomes

Primary

MeasureTime frame
I-PSS integral;QOLscore;

Countries

China

Contacts

Public ContactHongyue Niu

First Hospital Affiliated to Tianjin University of Traditional Chinese Medicine

nhy1966@sina.com+86 13820689368

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026